• Radiation Oncology Journal
• /
• 제32권2호
• /
• pp.95-98
• /
• 2014

Extramammary Paget disease (EMPD) is a rare disease, especially in Asian populations. Surgical resection is considered the primary treatment option. Recently, radiotherapy has been suggested as an EMPD treatment, either as an alternative to surgical resection or in combination with surgical resection. This report reviewed a patient with EMPD who was treated with wide excision of the EMPD site followed by radiotherapy for remaining gross lymph node metastases. The aim of this report was to determine the optimal treatment for advanced EMPD.

• 대한두경부종양학회지
• /
• 제1권1호
• /
• pp.81-86
• /
• 1985

A case of primary laryngeal non-Hodgkin's lymphoma is detailed with a review of the literature, on this rare site of presentation. Histologic findings and radio-therapeutic technique are included with longterm follow-up data. Local radiotherapy is a curative treatment of choice due to longterm NED survival with preservation of voice.

• Advances in Traditional Medicine
• /
• 제5권1호
• /
• pp.48-56
• /
• 2005

We studied the protective effect of Echinacea purpurea against radiation by evaluating changes in the peripheral blood cell count and peripheral blood antioxidant activity. Echinacea purpurea administration had a suppressive effect on radiation-induced leukopenia, especially on lymphocytes and monocytes and resulted in a faster recovery of blood cell counts. Mouse peripheral blood antioxidant activity was increased by Echinacea purpurea, and a relationship between the suppressive effect on radiation-induced leukopenia and the antioxidant effect was suggested.

• 대한두경부종양학회:학술대회논문집
• /
• 대한두경부종양학회 2008년도 추계학술대회 논문집
• /
• pp.268-268
• /
• 2008

• Nuclear Medicine and Molecular Imaging
• /
• 제41권4호
• /
• pp.309-316
• /
• 2007

감시 림프절 생검은 유방암 수술에서 림프절 전이 상태를 알기 위한 표준 시술이다. 환자는 방사성 콜로이드를 주사 받은 후 수술을 받게 된다. 이 과정에서 검사를 하는 핵의학과, 수술장, 유방암 검체를 다루는 병리과의 관계자는 미량이나마 환자와 검체에 의해서 방사선 피폭을 받을 수 있다. 이 연구의 목적은 감시 림프절 생검 과정, 특히 병리처리 과정에서 받는 방사선피폭을 정량하여 그 안전성을 확인하고 병리 시설과 폐기물에 대해서도 방사선 관련 안전성을 확인하는 것이다. 대상 및 방법 : 감시림프절 생검은 방사성 콜로이드를 이용하여 일반적인 임상적 방법으로 시행되었다. 병리기사, 핵의학 기사 및 핵의학 의사의 피폭량을 열형광선량계를 이용하여 1달간 측정하였다. 또한 작업과정중의 잔존 방사능량, 흡수선량, 작업시간, 작업거리, 조직폐기물 및 병리검사실의 공간선량을 측정하였다. 결과 전신 및 손의 피폭량은 병리기사에서 각각 0.21 및 0.85 uSv/study이었고 핵의학과 의사 및 핵의학과 기사의 전신피폭량은 각각 0.2 및 2.3 uSv/study 이었다. 일반인 기준(1000 uSv/year)으로 병리기사는 년간 약 1100건 감시림프절 관련 검체 처리를 할 수 있었다. 각 과정의 잔존방사성 및 피폭거리, 시간으로 측정한 피폭량은 수술의사는 전신/손의 피폭량이 건당 2.47/22.4 uSv 이었고 수술장간호사는 건당 0.22/0 uSv 이었다. 병리실의 공간선량률은 0.02-0.03 mR/hr로 방사성 관리구역의 설정 기준에 도달하지 않았다. 폐기되는 검체 조직의 방사능은 거의 측정되지 않아 100 Bq/g에 훨씬 미치지 않았다. 결론: 방사성동위원소를 이용한 감시림프절 검사에 관계된 병리처리과정은 방사선안전측면에서 일반적으로 안전하며 별도의 안전관리나 시설 없이 이루어 질 수 있다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권19호
• /
• pp.8215-8219
• /
• 2014

CD133 is one of the most important stem cell markers in solid cancers and Ki-67 is a marker that reflects cell proliferation. The relationships between the expression of CD133 and Ki-67 and prognosis in gastric carcinoma are unknown and need exploring. We examined 50 gastric cancer patients retrospectively in the Radiation Oncology Department of the Faculty of Medicine, Gazi University. CD133 and Ki-67 expression was examined using immunohistochemical staining. The survival rate in patients with CD133 positive expression was significantly worse than that in the patients with negative expression (p=0.04). Expression of CD133 had a positive correlation with that of Ki-67 (r=0.350; p=0.014). Multivariate analysis revealed that the expression of CD133 was an independent prognostic factor in gastric cancer (p=0.02). Conclusion, expression of CD133 may be a useful prognostic marker in gastric cancer.

• 대한두경부종양학회지
• /
• 제11권2호
• /
• pp.153-157
• /
• 1995

The effects of radiation therapy on salivary function of parotid gland were studied 20 male patients by radiation for tumors of head and neck. Saliva samples were collected before, during the radiotherapy and follow up. Parotid salivary function was quantitatively evaluated using a sialometry, sialochemistry, and scintigraphy. Salivary flow rates decreased in all individuals after irradiation. Glands than were partially irradiated were more likely to have some residual function than fully irradiated glands. Sodium and chloride contents were increased in parotid saliva of radiation patients where as potassium content was not changed definitively, pH was not changed during radiotherapy, but increased during follow up period. Scintigraphic stimulatory response rates showed similar result as flow rates. These results showed that exclusion of partial parotid gland from radiation is necessary to prevent severe xerostomia.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권1호
• /
• pp.53-58
• /
• 2015

Background: The purpose of this study was to assess the the efficacy of oral glutamine (GLN) in prevention of acute radiation-induced esophagitis in patients with lung cancer and determine the predictive role of clinical and dosimetric parameters. Materials and Methods: Thirty-two patients diagnosed with lung cancer were studied prospectively. Sixteen patients (50%) received prophylactic powdered GLN orally in doses of 10g/8h. Patients were treated 2 Gy per fraction daily, 5 days a week. We evaluated the grading of esophagitis daily at the end of each fraction of each treatment day until a cumulative dose of 50 Gy was reached. The primary end point was radiation-induced esophagitis. Results: All patients tolerated GLN well. Toxicity grade, weight loss, serum cytokine levels and esophageal transit times exhibited statistically significant improvement in the GLN receiving group. GLN suppressed the inflammation related to the disease and treatment and reduced toxicity with statistical significance. Conclusions: This study suggests a benefical role of oral GLN use in prevention and/or delay of radiation-induced esophagitis, in terms of esophageal transit time and serum immunological parameters, as well as weight loss.

• Brain & NeuroRehabilitation
• /
• 제10권1호
• /
• pp.1-6
• /
• 2017

The brain necrosis induced by radiation therapy (RT) is an uncommon pathology of brain. A case of spontaneous hemorrhage at necrotic brain is also rare. A 52-year-old man who had nasopharyngeal carcinoma and had been treated with RT, presented with gait disturbance, dizziness, ataxia, dysarthria, and dysphagia. Magnetic resonance imaging (MRI) demonstrated progressed radiation necrosis of pons, and spontaneous hemorrhage at the site of necrosis. The hematoma was diminished by conservative treatment. However, the patient's neurologic symptoms did not recover. Two years later, spontaneous bleeding recurred at necrotic brain. His neurologic symptoms worsened. One year later, his neurologic symptoms were more progressed. He showed severe dysphagia, profound weakness and respiratory failure. This case provides the description of relapsed spontaneous hemorrhage and medullary dysfunction caused by pontine necrosis and progressed post-radiation injury, complicated with hemorrhage, and urges caution in that the necrotic brain tissue may be vulnerable to bleeding.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권20호
• /
• pp.8911-8916
• /
• 2014

Background: The aim of the present study was to determine the predictive/prognostic value of the secreted protein, acidic and rich in cysteine (SPARC) in cases of unresectable, locally advanced, non-small cell lung cancer. Materials and Methods: The study included 84 patients with Stage IIIA-B non-small cell lung cancer, undergoing simultaneous chemoradiotherapy including radiotherapy at a dose of 66 Gy and weekly docataxel ($20mg/m^2$) and cisplatin ($20mg/m^2$). SPARC expression was studied in biopsy material by immunohistochemical methods and correlations with treatment responses or survival were evaluated. Results: Median overall survival was $16{\pm}2.73$ (11.55-20.46) months for low expression vs $7{\pm}1.79$ months (7.92-16.08) months for high expression (p=0.039), while median local control was $13{\pm}2.31$ (8.48-17.5) months for low expression vs $6{\pm}0.85$ (4.34-7.66) months for high expression (p=0.045) and median progression-free survival was $10{\pm}2.31$ (5.48-14.5) months for low expression vs $6{\pm}1.10$ (3.85-8.15) months for high expression (p=0.022). In both univariate and multivariate analyses, high SPARC expression was associated with significantly shorter overall survival (p=0.003, p=0.007, respectively), local control (p=0.008, p=0.036) and progression-free survival (p=0.004, p=0.029) when compared to low SPARC expression. No significant difference was detected between high and low SPARC expression groups regarding age, sex, T stage, N stage, histopathology and stage-related patient characteristics. Conclusions: High SPARC expression was identified as a poor prognostic factor in cases with locally advanced NSCLC treated with concurrent chemoradiotherapy.